Sean Khozin, MD, MPH is a physician-scientist and oncologist. He is the CEO of the CEO Roundtable on Cancer and the founder of PhyusionBio, focusing on advancing innovations at the intersection of biology, technology, and AI. 

Dr. Khozin is the former Chief Executive Officer of CancerLinQ, a precision oncology enterprise focused on transforming cancer care and research with real-world data and advanced analytics (acquired). He was previously the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative new medicines and vaccines.

Prior to this, he was a founding member of the US FDA’s Oncology Center of Excellence and Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that he established under special federal authorities. As a uniquely entrepreneurial sandbox housed within the agency responsible for regulating nearly a third of the US economy, INFORMED played a pivotal role in shaping the US FDA’s position on real-world evidence and catalyzing the use of novel data science solutions in drug discovery and clinical development.

Before his tenure in the US federal government, Dr. Khozin was the cofounder of Hello Health, a pioneering TechBio company focused on developing telemedicine, point-of-care data visualization, and analytical systems as an integrated approach for optimizing patient care, drug discovery, and clinical research (acquired). The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics he had founded called SKMD.

Dr. Khozin is a Research Affiliate at MIT, where he combines his quantitative and life sciences expertise in support of novel solutions for improving the lives of patients with cancer. He has over a decade of clinical and basic science research experience at the US National Cancer Institute, having started his clinical research work developing molecular profiling strategies for advancing the use of targeted therapies in thoracic malignancies.